Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
The first patient has been dosed in a Phase 3 clinical trial (NCT03491462) evaluating the effectiveness of Orphazyme’s investigational therapy arimoclomol in the treatment of amyotrophic lateral sclerosis (ALS). One of ... Read more
MND Scotland has initiated a clinical trial to test the tolerability and effectiveness of interleukin-2 in the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease ... Read more
The National Institute of Neurological Disorders and Stroke (NINDS) has awarded Aquinnah Pharmaceuticals $3.4 million to continue to develop and advance potential therapies to treat amyotrophic lateral sclerosis (ALS). ... Read more
Biohaven Pharmaceuticals has established an expanded access program (EAP) for patients with amyotrophic lateral sclerosis (ALS) for its investigational treatment candidate, BHV-0223, the company recently announced. The United States Food ... Read more
New technology that tests therapies designed for disorders of the neuromuscular junction, such as amyotrophic lateral sclerosis (ALS), closely mimics the human condition and offers a new method of ... Read more
The interaction between an RNA molecule and a protein is essential for the growth of axons, the portion of movement nerve cells responsible for communicating with other nerve cells, a study ... Read more
Pin It on Pinterest